If efficiently and safely scaled up in DMD patients, this technique could lead to one of the first successful genome editing-based treatments for this fatal disease, researchers said.
DMD, the most common and severe form of muscular dystrophy among boys, is characterized by progressive muscle degeneration and weakness. It is caused by mutations in the X-linked DMD gene that encodes the protein dystrophin. The disease affects one in 3,500 to 5,000 boys, according to the Centers for Disease Control and Prevention and other estimates, and often leads to premature death by the early 30s.
Although the genetic cause of DMD has been known for nearly 30 years, no effective treatments exist. The disease breaks down muscle fibers and replaces them with fibrous or fatty tissue, causing the muscle to gradually weaken. This condition often results in heart muscle disease, or cardiomyopathy, the leading cause of death in these patients.
In the study published today in Science, UTSW researchers used a gene-editing approach to permanently correct the DMD mutation that causes the disease in young mice.
“This is different from other therapeutic approaches, because it eliminates the cause of the disease,” said senior author Dr. Eric Olson, Chairman of Molecular Biology, and Co-Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center at UT Southwestern.
In 2014, Dr. Olson’s team first used this technique – called CRISPR/Cas9-mediated genome editing – to correct the mutation in the germ line of mice and prevent muscular dystrophy. This paved the way for novel genome editing-based therapeutics in DMD. It also raised several challenges for clinical applications of gene editing. Since germ line editing is not feasible in humans, strategies would need to be developed to deliver gene-editing components to postnatal tissues.
To test this out, researchers delivered gene-editing components to the mice via adeno-associated virus 9 (AAV9). DMD mice treated with this technique produced dystrophin protein and progressively showed improved structure and function of skeletal muscle and heart.
“AAV9 can efficiently infect humans in a tissue-specific manner, but it does not cause human disease or toxicity. It’s a molecular missile for gene therapy,” said Dr. Leonela Amoasii, a postdoctoral researcher in the Olson lab and co-lead author of the study with Dr. Chengzu Long, Instructor of Molecular Biology.
“The CRISPR/Cas9 system is an adaptive immune system of single-celled organisms against invading virus. Ironically, this system was hijacked, we packaged it into a nonpathogenic virus, and corrected a genetic mutation in an animal model,” added Dr. Long.
The CRISPR genome-editing technology, which was developed by a researcher at University of California at Berkeley, was picked as the “Breakthrough of the Year” scientific development by Science.
“This study represents a very important translational application of genome editing of DMD mutations in young mice. It’s a solid step toward a practical cure for DMD,” said Dr. Rhonda Bassel-Duby, Professor of Molecular Biology and Co-Principal Investigator of a genomic editing project with Dr. Olson at the Wellstone Center.
“Importantly, in principle, the same strategy can be applied to numerous types of mutations within the human DMD patients,” added Dr. Olson, who also serves as Director of the Hamon Center for Regenerative Science and Medicine, and holds the Annie and Willie Nelson Professorship in Stem Cell Research, the Pogue Distinguished Chair in Research on Cardiac Birth Defects, and the Robert A. Welch Distinguished Chair in Science.
Now, the research team is working to apply this gene-editing technique to cells from DMD patients and in larger preclinical animal models.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Santhera Announces Publication of Long-term Idebenone Data from SYROS Study in Duchenne Muscular Dystrophyon November 19, 2019 at 7:48 pm
Buyse, MD, PhD, Professor of Pediatrics and Child Neurology, University Hospitals Leuven (Leuven, Belgium). About Duchenne Muscular Dystrophy DMD is one of the most common and devastating types of ...
- Duchenne Muscular Dystrophy: Rep. Frey, Gov. Lamont raise awareness for rare diseaseon November 19, 2019 at 1:51 pm
Frey said. During a meeting in Governor Lamont’s Capitol office, the Currans shared that hearing the diagnosis of Duchenne Muscular Dystrophy was heartbreaking for them and devastating for Conner, ...
- Press Release: Santhera Announces Publication of Long-term Idebenone Data from SYROS Study in Duchenne Muscular Dystrophyon November 18, 2019 at 10:03 pm
reduced from -5.9% 'Off-Idebenone' to -1.9% 'On-Idebenone'. -- The annual rate of decline in FVC%p and PEF%p remained stable year after year for the entire follow-up time of up to six years and was ...
- A distant dream for us with muscular dystrophyon November 17, 2019 at 11:56 pm
Early symptoms include a wadding gait, pain and stiffness in muscles, difficulty sitting up or standing, walking on toes, frequent falls etc. Most common and severe form of muscular dystrophy is ...
- Becker muscular dystrophy caused by exon 2-truncating mutation of DMDon November 17, 2019 at 7:28 pm
Nonsense and frameshift mutations of the dystrophin (DMD) gene usually cause severe Duchenne muscular dystrophy (DMD). Interestingly, however, premature stop codons in exons 1 and 2 result in ...
- Duchenne Muscular Dystrophy Therapeutics Market Strategic Assessment by Top Players | Sarepta Therapeutics, Inc, Santhera Pharmaceuticalson November 13, 2019 at 8:33 pm
Nov 14, 2019 (WiredRelease via COMTEX) -- Duchenne Muscular Dystrophy Therapeutics Market by Growth 2020 – Technological Strategies, Business Advancements and Top-Vendor Landscape 2029, anticipated to ...
- Parent Project Muscular Dystrophy Launches New Duchenne Registry Appon November 12, 2019 at 4:23 pm
Leading Duchenne Organization Enhances 12-Year-Old Registry with New App, Empowering Families to Become Citizen Scientists by Contributing Data from the Palm of their Hand HACKENSACK, N.J., Nov. 12, ...
- University Of Pennsylvania Testing New Gene Therapy Targeting Duchenne Muscular Dystrophyon November 12, 2019 at 3:35 pm
PHILADELPHIA (CBS) — A new gene therapy treatment is being tested at the University of Pennsylvania to treat a rare kind of muscular dystrophy. It’s progressive and strikes mainly boys. One ...
- Trial of Gene Therapy for Duchenne Muscular Dystrophy Put on Holdon November 12, 2019 at 11:35 am
A clinical trial of a gene therapy for Duchenne muscular dystrophy has been halted after a patient suffered serious side effects following treatment, Reuters reports today (November 12). After ...
- Cresswell mum tells of her brave boys' battle with Duchenne Muscular Dystrophyon November 12, 2019 at 7:53 am
Elizabeth and Scott Ruthven were heartbroken when first their son Wyatt, four and then Garret aged two were told they had Duchenne Muscular Dystrophy, a progressive muscle wasting condition. There is ...
via Bing News